Pascal Wolter

8.4k total citations
86 papers, 2.0k citations indexed

About

Pascal Wolter is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Pascal Wolter has authored 86 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Pascal Wolter's work include Renal cell carcinoma treatment (26 papers), Melanoma and MAPK Pathways (13 papers) and Lymphoma Diagnosis and Treatment (11 papers). Pascal Wolter is often cited by papers focused on Renal cell carcinoma treatment (26 papers), Melanoma and MAPK Pathways (13 papers) and Lymphoma Diagnosis and Treatment (11 papers). Pascal Wolter collaborates with scholars based in Belgium, United States and France. Pascal Wolter's co-authors include Patrick Schöffski, Herlinde Dumez, Brigitte Decallonne, Benoit Beuselinck, Cristiana Stefan, Gregor Verhoef, Hendrik Van Poppel, Veerle Foulon, M Bex and Evelyne Lerut and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Pascal Wolter

81 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pascal Wolter Belgium 26 1000 817 790 308 165 86 2.0k
Choong‐kun Lee South Korea 21 688 0.7× 535 0.7× 490 0.6× 312 1.0× 100 0.6× 100 1.6k
Laura Pizzuti Italy 23 906 0.9× 454 0.6× 333 0.4× 410 1.3× 79 0.5× 96 1.7k
Ryusei Saito Japan 26 1.1k 1.1× 1.1k 1.3× 1.2k 1.5× 373 1.2× 189 1.1× 88 2.4k
Ryuichi Mizuno Japan 28 926 0.9× 1.1k 1.3× 1.2k 1.5× 526 1.7× 156 0.9× 205 2.6k
Christine Walsh United States 30 874 0.9× 845 1.0× 349 0.4× 391 1.3× 215 1.3× 93 2.6k
Yan Qin China 22 781 0.8× 641 0.8× 405 0.5× 386 1.3× 209 1.3× 131 1.8k
Fumihiko Hirai Japan 26 1.1k 1.1× 439 0.5× 979 1.2× 181 0.6× 211 1.3× 103 1.8k
Puja Gaur United States 25 646 0.6× 685 0.8× 482 0.6× 311 1.0× 174 1.1× 66 1.8k
António Araújo Portugal 21 698 0.7× 624 0.8× 540 0.7× 460 1.5× 106 0.6× 119 1.6k
Gavin Marx Australia 24 662 0.7× 466 0.6× 735 0.9× 471 1.5× 76 0.5× 100 1.8k

Countries citing papers authored by Pascal Wolter

Since Specialization
Citations

This map shows the geographic impact of Pascal Wolter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Wolter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Wolter more than expected).

Fields of papers citing papers by Pascal Wolter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Wolter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Wolter. The network helps show where Pascal Wolter may publish in the future.

Co-authorship network of co-authors of Pascal Wolter

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Wolter. A scholar is included among the top collaborators of Pascal Wolter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Wolter. Pascal Wolter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Segers, Karin, Pascal Wolter, Joëlle Collignon, et al.. (2024). Digenic Inheritance of Mutations in Homologous Recombination Genes in Cancer Patients. Journal of Personalized Medicine. 14(6). 584–584.
2.
Agazzi, Giorgio Maria, Frederik De Keyzer, Olivier Gheysens, et al.. (2021). Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome. Radiology Imaging Cancer. 3(2). e200061–e200061. 2 indexed citations
3.
Vanmechelen, Maxime, Diether Lambrechts, Thomas Van Brussel, et al.. (2018). Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer. 17(2). e235–e246. 4 indexed citations
4.
Whittaker, Sean, Steve Horwitz, Madeleine Duvic, et al.. (2017). 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology. 137(5). S45–S45. 1 indexed citations
5.
Sznol, Mario, Pier Francesco Ferrucci, David Hogg, et al.. (2016). Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL). Annals of Oncology. 27. vi385–vi385. 2 indexed citations
6.
Wolter, Pascal, Patrick Schöffski, Johan Van Cleemput, et al.. (2016). A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy. Clinical Genitourinary Cancer. 15(1). e155–e158.
7.
Francke, Stephan, Pascal Wolter, Stefanie Hauser, et al.. (2016). An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene. 36(1). 110–121. 35 indexed citations
8.
Rogiers, Aljosja, Joost J. van den Oord, Marjan Garmyn, et al.. (2015). Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. Drugs & Aging. 32(10). 821–834. 12 indexed citations
9.
Tuominen, Rainer, Rosalyn Jewell, Joost J. van den Oord, et al.. (2014). MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma. International Journal of Cancer. 136(12). 2844–2853. 40 indexed citations
10.
Wolter, Pascal, et al.. (2013). Physical Activity and Risk of Lymphoma: A Meta-Analysis. Cancer Epidemiology Biomarkers & Prevention. 22(7). 1173–1184. 14 indexed citations
11.
Bamias, Aristotelis, Kimon Tzannis, Benoit Beuselinck, et al.. (2013). Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. British Journal of Cancer. 109(2). 332–341. 23 indexed citations
12.
Wolter, Pascal, et al.. (2013). Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Annals of Hematology. 92(8). 1007–1021. 25 indexed citations
13.
Keyzer, Frederik De, Pascal Wolter, Olivier Gheysens, et al.. (2013). Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging. 13(1). 53–62. 34 indexed citations
14.
15.
Beuselinck, Benoit, Pascal Wolter, Alexandra Karadimou, et al.. (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer. 107(10). 1665–1671. 86 indexed citations
16.
Schöffski, Patrick, Ahmad Awada, Herlinde Dumez, et al.. (2011). A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. European Journal of Cancer. 48(2). 179–186. 132 indexed citations
17.
Włodarska, Iwona, Thomas Tousseyn, Laurence de Leval, et al.. (2009). Novel t(x;14)(p11.4;q32.33) resulting in upregulation of gpr34 and activation of the nfkb pathway is recurrent in malt lymphomas. Haematologica. 94. 271–272. 3 indexed citations
18.
Eisen, Tim, José Thomas, Wilson H. Miller, et al.. (2009). Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Research. 19(3). 185–192. 28 indexed citations
19.
Wolter, Pascal, et al.. (2006). Thyroid dysfunction in patients treated with Sunitinib (SU11248) - A single center retrospective and prospective evaluation. Annals of Oncology. 17. 136–136.
20.
Schöffski, Patrick, Herlinde Dumez, Paul M. Clément, et al.. (2006). Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology. 17(8). 1185–1196. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Choong‐kun Lee Breakdown of academic impact, for papers by Laura Pizzuti Breakdown of academic impact, for papers by Ryusei Saito Breakdown of academic impact, for papers by Ryuichi Mizuno Breakdown of academic impact, for papers by Christine Walsh Breakdown of academic impact, for papers by Yan Qin Breakdown of academic impact, for papers by Fumihiko Hirai Breakdown of academic impact, for papers by Puja Gaur Breakdown of academic impact, for papers by António Araújo Breakdown of academic impact, for papers by Gavin Marx
Rankless by CCL
2026